Tamara van Donge

General discussion and future perspectives 239 11 References 1. Engbers AG, Flint RB, Völler S, et al. Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus. British journal of clinical pharmacology. 2020;86(10):2028- 2039. 2. Flint RB, Ter Heine R, Spaans E, et al. Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns. European journal of clinical pharmacology. 2018;74(12):1585-1591. 3. Allegaert K, Flint R, Smits A. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle. Expert opinion on drug metabolism & toxicology. 2019;15(9):735-749. 4. Smits A, De Cock R, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe C. PROSPECTIVE VALIDATION OF A MODEL-BASED DOSING REGIMEN FOR AMIKACIN IN NEONATES: FEASIBLE AND RELEVANT. In: BMJ Publishing Group Ltd; 2016. 5. Koch G, Datta AN, Jost K, Schulzke SM, van den Anker J, Pfister M. Caffeine citrate dosing adjustments to assure stable caffeine concentrations in preterm neonates. The Journal of pediatrics. 2017;191:50-56. e51. 6. De Cock RF, Smits A, Allegaert K, et al. Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. Journal of Antimicrobial Chemotherapy. 2014;69(5):1330-1338. 7. Mathias B, Mira J, Larson SD. Pediatric sepsis. Current opinion in pediatrics. 2016;28(3):380. 8. Van Donge T, Pfister M, Bielicki J, et al. Quantitative analysis of gentamicin exposure in neonates and infants calls into question its current dosing recommendations. Antimicrobial agents and chemotherapy. 2018;62(4). 9. Marchand S, Chauzy A, Dahyot-Fizelier C, Couet W. Microdialysis as a way to measure antibiotics concentration in tissues. Pharmacological research. 2016;111:201-207. 10. Sy SK, Zhuang L, Derendorf H. Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. Expert opinion on drug metabolism & toxicology. 2016;12(1):93-114. 11. Standing JF. Understanding and applying pharmacometric modelling and simulation in clinical practice and research. British journal of clinical pharmacology. 2017;83(2):247-254. 12. van Donge T, Fuchs A, Leroux S, et al. Amoxicillin Dosing Regimens for the Treatment of Neonatal Sepsis: Balancing Efficacy and Neurotoxicity. Neonatology. 2020;117(5):619-627. 13. Tang B-H, Wu Y-E, Kou C, et al. Population pharmacokinetics and dosing optimization of amoxicillin in neonates and young infants. Antimicrobial agents and chemotherapy. 2019;63(2). 14. Flint RB, van Beek F, Andriessen P, et al. Large differences in neonatal drug use between NICUs are common practice: time for consensus? British journal of clinical pharmacology. 2018;84(6):1313- 1323. 15. Krans EE, Patrick SW. Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic. Obstetrics and gynecology. 2016;128(1):4. 16. Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstetrics and gynecology. 2014;123(5):997. 17. Huybrechts KF, Bateman BT, Desai RJ, et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. bmj. 2017;358. 18. Ross EJ, Graham DL, Money KM, Stanwood GD. Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. Neuropsychopharmacology. 2015;40(1):61-87.